To summarize studies using omics technologies to advance understanding of secondary lymphedema (LE) and identify candidate biomarkers, cell populations, signaling pathways, and therapeutic targets.
Approach:
Omics Technologies: The review discusses the application of transcriptomic, proteomic, metabolomic, lipidomic, and genomic approaches in secondary LE.
Key Findings:
Omics technologies provide insights into inflammatory, fibrotic, metabolic, and genetic factors influencing secondary LE.
Transcriptomic analyses have identified differentially expressed genes in adipose tissue and lymphatic cells associated with LE.
Key upregulated genes in LE include PTX3, AREG, IL6, VEGFC, FLT4, and TNC.
TIE2 signaling pathways are significantly affected in LE, with potential therapeutic implications from targeting this pathway.
Interpretation:
The integration of omics data enhances the understanding of secondary LE pathophysiology.
Limitations:
Current studies have methodological limitations related to sample types and bioinformatic analysis.
There is a need for more comprehensive multi-omics strategies.
Conclusion:
Future research should focus on multi-omics approaches to improve diagnosis, risk stratification, and treatment development for secondary lymphedema.
by Annica R. Stull-Lane, Xizhao Chen, Abraham J. Book, Radomir Kratchmarov, Sarit Pal, Jinyeon Shin, Gopika Ashokan, Geoffrey E. Hespe, Babak J. Mehrara, Raghu P. Kataru
